Read more about the article RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59

RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59

Continue ReadingRedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59
Read more about the article Entera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged.

Entera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged.

Continue ReadingEntera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged.